Table 12.6a

Immunosuppression Use for Induction, 1993 to 2002

Recipients with Lung Transplants

	Year of Transplant
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants	674	738	893	836	947	893	919	976	1,073	1,054
Tx With Immunosuppression Info	666	730	879	760	930	885	893	945	1,049	977
No Induction Drugs Recorded	97.0%	74.8%	71.4%	73.7%	78.2%	77.5%	69.4%	56.7%	60.5%	58.9%
Drugs	-	0.0%	0.0%	-	-	-	-	-	-	-
ALG
ATG	0.8%	19.0%	23.2%	20.5%	17.5%	12.2%	11.6%	11.3%	9.0%	6.8%
NRATG/NRATS	-	0.0%	0.1%	2.2%	2.0%	1.7%	1.0%	0.6%	-	-
OKT3	2.3%	6.2%	5.2%	3.7%	2.5%	3.5%	3.4%	2.6%	1.0%	0.6%
Thymoglobulin	-	-	-	-	-	-	1.9%	6.0%	5.5%	8.8%
Zenapax	-	-	-	-	-	4.9%	9.6%	14.7%	11.4%	13.9%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	3.2%	8.4%	13.0%	11.5%

Source: OPTN/SRTR Data as of August 1, 2003.

(-) = Drug not used anytime during the year.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.